Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antineoplastic agent |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
P01CA02
|
| gptkbp:CASNumber |
22994-85-0
|
| gptkbp:chemicalFormula |
C12H12N4O3
|
| gptkbp:contraindication |
severe kidney disease
severe liver disease |
| gptkbp:developedBy |
1970s
|
| gptkbp:discoveredBy |
gptkb:Roche
|
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Benznidazol
|
| gptkbp:KEGGID |
D02697
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits DNA synthesis in Trypanosoma cruzi
|
| gptkbp:MedlinePlusID |
a617007
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
2327
DB11989 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
peripheral neuropathy rash |
| gptkbp:synonym |
gptkb:benznidazole
|
| gptkbp:UNII |
U3G4E0XK6X
|
| gptkbp:usedFor |
gptkb:Chagas_disease
|
| gptkbp:WHOModelListOfEssentialMedicines |
true
|
| gptkbp:bfsParent |
gptkb:benznidazole
|
| gptkbp:bfsLayer |
7
|